Resveratrol and anti-atherogenic effects

International Journal of Food Sciences and Nutrition

Volumn 66, Issue 6, 2015, Pages 603-610

  Riccioni, Graziano ^a   Gammone, Maria Alessandra ^b   Tettamanti, Guido ^c   Bergante, Sonia ^c   Pluchinotta, Francesca Romana ^c   D'Orazio, Nicolantonio ^b  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Anti inflammatory; Antioxidant; Atherosclerosis; Cardiovascular disease; Lipids; Polyphenol; Prevention

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; RESVERATROL; STILBENE DERIVATIVE;

ARTERIOSCLEROSIS; HUMAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTERIOSCLEROSIS; HUMANS; STILBENES;

EID: 84945926158     PISSN: 09637486     EISSN: 14653478     Source Type: Journal    
DOI: 10.3109/09637486.2015.1077796     Document Type: Note

References (98)

1. Agarwal B, Campen MJ, Channell MM, Wherry SJ, Varamini B, Davis JG. 2013. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol 166:246-248.
2. Ahn J, Cho I, Kim S, Kwon D, Ha T. 2008. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 49:1019-1028.
3. Almeida L, Vaz-da-Silva M, Falcao A. 2009. Pharamacokinetic and safety of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53:S7-15.
4. Bertelli AA, Giovannini L, Bernini W, Migliori M, Fregoni M, Bavaresco L. 1996a. Antiplatelet activity of cis-resveratrol. Drug Exp Clin Res 22:61-63.
5. Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP, Bertelli A. 1996b. Kinetics of trans- and cis-resveratrol (3,40,5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res 16:77-81.
6. Bhat KPL, Kosmeder JW, Pezzuto JM. 2001. Biological effects of resveratrol. Antioxid Redox Signal 3:1041-1064.
7. Boocock DJ, Faust GE, Patel KR. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252.
8. Cao X, Luo T, Luo X, Tang Z. 2014. Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. Hypertens Res 37:803-810.
9. Carluccio MA, Siculella L, Ancora MA, Massaro M, Scoditti E, Storelli C. 2003. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 23:622-629.
10. Cavallaio A, Ainis T, Bottari C, Figiani V. 2003. Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol Res 52:555-562.
11. Chen M-l, Yi L, Jin X, Xie Q, Zhang T, Zhou X. 2013a. Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway. J Nutr Biochem 24:1823-1829.
12. Chen ML, Yi L, Jin X, Liang XY, Zhou Y, Zhang T. 2013b. Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway. Autophagy 9:2033-2045.
13. Cho IJ, Ahn JY, Kim S, Choi MS, Ha TY. 2008. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun 367:190-194.
14. Cottart CH, Nivet-Antoine V, Beaudeux JL. 2014. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res 58:7-21.
15. Csiszar A, Smith K, Labinskyy N, Orosz Z, Rivera A, Ungvari Z. 2006. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition. Am J Physiol Heart Circ Physiol 291:H1694-1699.
16. Csizar A, Labinskyy N, Pinto JT. 2009. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 297:H13-20.
17. Culpitt SV, Rogers DF, Fenwick PS, Shah P, DeMatos C, Russell RE. 2003. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58:942-946.
18. D'Orazio N, Gammone MA, Gemello E, DeGirolamo M, Cusenza S, Riccioni G. 2012a. Marine bioactives: pharmacological properties and potential applications against inflammatory diseases. Mar Drugs 10:812-833.
19. D'Orazio N, Gemello E, Gammone MA, DeGirolamo M, Ficoneri C, Riccioni G. 2012b. Fucoxantin: a treasure from sea. Mar Drugs 10:604-644.
20. Das S, Tosaki A, Bagchi D, Maulik N, Das DK. 2005. Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J Pharmacol Exp Ther 314:762-769.
21. Davignon J, Ganz P. 2004. Role of endothelial dysfunction in atherosclerosis. Circulation 109:III27-32.
22. De Santi C, Pietrabissa A, Mosca F, Pacifici GM. 2000. Glucuronidation of resveratrol, a natural product in grape and wine, in the human liver. Xenobiotica 30:1047-1054.
23. Donnelly LE, Newton R, Kennedy GE, Fenwick PS, Leung RH, Ito K. 2004. Anti-inflammatory effects of resveratrol in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 287:L774-783.
24. Fan E, Zhang L, Jiang S, Bai Y. 2008. Beneficial effects of resveratrol on atherosclerosis. J Med Food 11:610-614.
25. Fauconneau B, Waffo-Teguo P, Huguet F, Barrie L, Decendit A, Merillon JM. 1997. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis Vinifera cell cultures using in vitro tests. Life Sci 61:2103-2110.
26. Frankel EN, Waterhouse AL. 1993. Inhibition of human LDL oxidation by resveratrol. Lancet 341:1103-1104.
27. Fremont L. 2000. Biological effects of resveratrol. Life Sci 66:663-673.
28. Gammone MA, D'Orazio N. 2015. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar Drugs 13:2196-2214.
29. Gammone MA, Gemello E, Riccioni G, D'Orazio N. 2014a. Marine bioactives and potential application in sports. Mar Drugs 12:2357-2382.
30. Gammone MA, Riccioni G, D'Orazio N. 2015. Carotenoids: potential allies of cardiovascular health? Food Nutr Res 59:26762.
31. Goldberg DM, Yan J, Soleas GJ. 2003. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79-87.
32. Goldberg DM, Hahn SE, Parkes JG. 1995. Beyond alcohol: beverage consumption and cardiovascular mortality. Clin Chim Acta 237:155-187.
33. Gu XS, Wang ZB, Ye Z, Lei JP, Li L, Su DF, Zheng X. 2014. Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet. Mol. Res. 13:323-335.
34. Haider UG, Roos TU, Kontaridis MI, Neel BG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM. 2005. Resveratrol inhibits angiotensin II- and epidermal growth factor-mediated Akt activation: role of Gab-1 and Shp-2. Mol Pharmacol 68:41-48.
35. Hattori R, Otani H, Maulik N, Das DK. 2002. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 282:H1988-1995.
36. Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ. 2005. Toxicogenomics of resveratrol in rat liver. Life Sci 76:2299-2314.
37. Holvoet P. 2004. Oxidized LDL and coronary heart disease. Acta Cardiol 59:479-484.
38. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. 2000. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 47:549-555.
39. Ikeda U, Ito T, Shimada K. 2001. Interleukin-6 and acute coronary syndrome. Clin Cardiol 24:701-704.
40. Imamura G, Bertelli AA, Bertelli A, Otani H, Maulik N, Das DK. 2002. Pharmacologic preconditioning with resveratrol: an insight with iNOS knockout mice. Am J Physiol 282:H1996-2003.
41. Jang JH, Surh YJ. 2001. Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat Res 496:181-190.
42. Jawien J. 2008. New insights into immunological aspects of atherosclerosis. Pol Arch Med Wewn 118:127-131.
43. Kaur G, Rao LVM, Pendurthi UR. 2007. Effect of wine phenolics on cytokine-induced C-reactive protein expression. J Thromb Haemost 5:1309-1317.
44. Kirk RI, Deitch JA, Wu JM, Lerea KM. 2000. Resveratrol decreases early signalling events in washed platelets but has little effect on platelet in whole blood. Blood Cells Mol Dis 26:144-210.
45. Kovanen PT, Pentikäinen MO. 2003. Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis. Curr Opin Lipidol 14:411-419.
46. Leiro J, Alvarez E, Arranz JA, Laguna R, Uriarte E, Orallo F. 2004. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol 75:1156-1165.
47. Leonard S, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK. 2003. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309:1017-1026.
48. Li Y, Cao Z, Zhu H. 2006. Up-regulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cyto-protection against oxidative and electrophilic stress. Pharmacol Res 53:6-15.
49. Libby P, Ridker PM, Maseri A. 2002. Inflammation and atherosclerosis. Circulation 105:1135-1143.
50. Lin MT, Yen ML, Lin CY, Kuo ML. 2003. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 64:1029-1036.
51. Liu Z, Jiang C, Zhang J, Liu B, Du Q. 2015. Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation ofAMP-activated protein kinase and sirtuin 1 activities. J Diabetes 10:1111-1153.
52. Losa GA. 2003. Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur J Clin Invest 33:818-823.
53. Martinez J, Moreno JJ. 2000. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 59:865-870.
54. Masuelli L, Marzocchella L, Focaccetti C, Tresoldi I, Palumbo C, Izzi V, Benvenuto M, et al. 2012. Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis. Front Biosci (Landmark Ed) 17:498-508.
55. Meng X, Maliakal P, Lu H, Lee MJ, Yang CS. 2004. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 52:935-942.
56. Mietus-Snyder M, Gowri MS, Pitas RE. 2000. Class A scavenger receptor up-regulation in smooth muscle cells by oxidized low density lipoprotein. Enhancement by calcium flux and concurrent cyclooxygenase-2 up-regulation. J Biol Chem 275:17661-17670.
57. Miller NJ, Rice-Evans CA. 1995. Antioxidant activity of resveratrol in red wine. Clin Chem 41:1788-1790.
58. Miura T, Muraoka S, Ikeda N, Watanabe M, Fujimoto Y. 2000. Antioxidative and pro-oxidative action of stilbene derivatives. Pharmacol Toxicol 86:203-208.
59. Miura D, Miura Y, Yagasaki K. 2003. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma bearing rats. Life Sci 73:1393-1400.
60. Mizutani K, Ikeda K, Kawai Y, Yamori Y. 2001. Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 28:55-59.
61. Mokni M, Limam F, Elkahoui S, Amri M, Aouani E. 2007. Strong cardioprotective effect of resveratrol, a red wine polyphenol, on isolated rat hearts after ischemia/reperfusion injury. Arch Biochem Biophys 457:1-6.
62. Novelle MG, Wahl D, Diéguez C, Bernier M, de Cabo R. 2015. Resveratrol supplementation: where are we now and where should we go? Ageing Res Rev 21:1-15.
63. Olas B, Wachowicz B. 2002. Resveratrol and vitamin C as antioxidants in blood platelets. Thromb Res 106:143-148.
64. Olas B, Wachowicz B, Bald E, Glowacki R. 2004. The protective effects of resveratrol against changes in blood platelet thiols induced by platinum compounds. J Physiol Pharmacol 55:467-476.
65. Olas B, Wachowicz B, Saluk-Juszczak J, Zielinski T. 2002. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb Res 107:141-145.
66. Pal S, Ho N, Santos C, Dubois P, Mamo J, Croft K. 2003. Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutr 133:700-706.
67. Pallauf K, Giller K, Huebbe P, Rimbach G. 2013. Nutrition and healthy ageing: caloric restriction or polyphenol-rich 'MediterrAsian' diet? Oxid Med Cell Longev 2013:707421.
68. Penumathsa SV, Thirunavukkarasu M, Koneru S, Juhasz B, Zhan L, Pant R. 2007. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 42:508-516.
69. Pervaiz S. 2003. Resveratrol: from grapevines to mammalian biology. FASEB J 17:1975-1985.
70. Peserico A, Chiacchiera F, Grossi V, Matrone A, Latorre D, Simonatto M. 2013. A novel AMPK-dependent FoxO3A-SIRT3 intramitochondrial complex sensing glucose levels. Cell Mol Life Sci 70:2015-2029.
71. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, et al. 2012. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675-690.
72. Ray PS, Maulik G, Cordis GA, Bertelli A, Das DK. 1999. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Rad Biol Med 27:160-169.
73. Riccioni G, De Santis A, Cerasa V, Menna V, Di Ilio C, Schiavone C, Ballone E, D'Orazio N. 2003. Atherosclerotic plaque formation and risk factors. Int J Immunopathol Pharmacol 16:25-31.
74. Riccioni G, Bucciarelli T, Mancini B, Corradi F, Di Ilio C, Mattei PA, D'Orazio N. 2007. Antioxidant vitamin supplementation in cardiovascular diseases. Ann Clin Lab Sci 37:89-95.
75. Rivera L, Moron R, Zarzuelo A, Galisteo M. 2009. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77:1053-1063.
76. Rocha KK, Souza GA, Ebaid GX, Seiva FR, Cataneo AC, Novelli EL. 2009. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol 47:1362-1367.
77. Sahebkar A. 2013. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 71:822-835.
78. Sato M, Maulik G, Bagchi D, Das DK. 2000. Myocardial protection by protykin, a novel extract of transresveratrol and emodin. Free Radic Res 32:135-144.
79. Sato M, Maulik N, Das DK. 2002. Cardioprotection with alcohol:role of both alcohol and polyphenolic antioxidants. Ann NY Acad Sci 957:122-135.
80. Shigematsu S, Ishida S, Hara M, Takahashi N, Yoshimatsu H, Sakata T. 2003. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 34:810-817.
81. Soares DG, Andreazza AC, Salvador M. 2003. Sequestering ability of butylated hydroxytoluene, propyl gallate, resveratrol, and vitamins C and E against ABTS, DPPH, and hydroxyl free radicals in chemical and biological systems. J Agric Food Chem 51:1077-1080.
82. Soleas GJ, Diamandis EP, Goldberg DM. 1997. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30:91-113.
83. Stef G, Csiszar A, Lerea K, Ungvari Z, Veress G. 2006. Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovasc Pharmacol 48:1-5.
84. Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP. 2010. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 298:H833-843.
85. Sun W, Wang W, Kim J, Keng P, Yang S, Zhang H. 2008. Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exp Med Biol 614:179-186.
86. Sun AY, Simony A, Sun GY. 2002. The 'French Paradox' and beyond: neuroprotective effects of polyphenols. Free Radic Biol Med 32:314-318.
87. Sun Y, Li J, Xiao N, Wang M, Kou J, Qi L, Huang F, et al. 2014. Pharmacological activation of AMPK ameliorates perivascular adipose/endothelial dysfunction in a manner interdependent on AMPK and SIRT1. Pharmacol Res. 89:19-28.
88. Szewczuk LM, Forti L, Stivala LA, Penning TM. 2004. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 279:22727-22737.
89. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. 2008. Potential of resveratrol in anti-cancer and anti-inflammatory therapy. Nutr Rev 66:445-454.
90. Vaz-da-Silva M, Loureiro AI, Falcao A. 2008. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther 46:564-570.
91. Walle T, Hsieh F, DeLegge MH. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377-1382.
92. Wallerath T, Deckert G, Ternes T. 2002a. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances the expression and activity of endothelial nitric oxide synthase. Circulation 106:1652-1658.
93. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U. 2002b. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106:1652-1658.
94. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY. 2002a. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 958:439-447.
95. Wang Z, Zou J, Huang Y, Cao K, Xu Y, Wu JM. 2002b. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl) 115:378-380.
96. Yen GC, Duh PD, Lin CW. 2003. Effects of resveratrol and 4-hexylresorcicol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res 37:509-514.
97. Zhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY, Zhang JT. 1999. Inhibitory effect of resveratrol on interleukin-6 release by stimulated peritoneal macrophages of mice. Phytomedicine 6:79-84.
98. Zhou X, Chen M, Zeng X, Yang J, Deng H, Yi L, Mi MT. 2014. Resveratrol regulates mitochondrial reactive oxygen species homeostasis through Sirt3 signaling pathway in human vascular endothelial cells. Cell Death Dis 5:e1576.